US4885242A
(en)
*
|
1984-10-30 |
1989-12-05 |
Phillips Petroleum Company |
Genes from pichia histidine pathway and uses thereof
|
US4855231A
(en)
*
|
1984-10-30 |
1989-08-08 |
Phillips Petroleum Company |
Regulatory region for heterologous gene expression in yeast
|
US4818700A
(en)
*
|
1985-10-25 |
1989-04-04 |
Phillips Petroleum Company |
Pichia pastoris argininosuccinate lyase gene and uses thereof
|
US4882279A
(en)
*
|
1985-10-25 |
1989-11-21 |
Phillips Petroleum Company |
Site selective genomic modification of yeast of the genus pichia
|
US4895800A
(en)
*
|
1985-11-26 |
1990-01-23 |
Phillips Petroleum Company |
Yeast production of hepatitis B surface antigen
|
ZA872534B
(en)
*
|
1986-05-08 |
1987-11-25 |
Phillips Petroleum Co |
Yeast production of streptokinase
|
US5258287A
(en)
*
|
1988-03-22 |
1993-11-02 |
Genentech, Inc. |
DNA encoding and methods of production of insulin-like growth factor binding protein BP53
|
IL89989A0
(en)
*
|
1988-04-25 |
1989-12-15 |
Phillips Petroleum Co |
Expression of human interleukin-2 in methylotrophic yeasts
|
NZ228774A
(en)
*
|
1988-04-25 |
1991-05-28 |
Phillips Petroleum Co |
Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
|
US5204252A
(en)
*
|
1989-02-08 |
1993-04-20 |
Henkel Research Corporation |
Candida tropicalis transformation system
|
WO1990009434A1
(en)
*
|
1989-02-13 |
1990-08-23 |
The Salk Institute Biotechnology/Industrial Associates, Inc. |
Production of superoxide dismutase in pichia pastoris yeast cells
|
US5254466A
(en)
*
|
1989-11-06 |
1993-10-19 |
Henkel Research Corporation |
Site-specific modification of the candida tropicals genome
|
US5612198A
(en)
*
|
1990-09-04 |
1997-03-18 |
The Salk Institute |
Production of insulin-like growth factor-1 in methylotrophic yeast cells
|
WO1992013951A1
(en)
*
|
1991-02-04 |
1992-08-20 |
The Salk Institute Biotechnology/Industrial Associates, Inc. |
Production of human serum albumin in methylotrophic yeast cells
|
ATE220105T1
(de)
*
|
1991-04-01 |
2002-07-15 |
Merck & Co Inc |
Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
|
US6872550B1
(en)
*
|
1991-07-11 |
2005-03-29 |
Baxter Vaccine Ag |
Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
|
US5665600A
(en)
*
|
1991-09-18 |
1997-09-09 |
Research Corporation Technologies, Inc. |
Pichia pastoris linear plasmids and DNA fragments thereof
|
JP3559559B2
(ja)
|
1992-06-03 |
2004-09-02 |
ジェネンテク,インコーポレイテッド |
向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
|
WO1994020631A2
(en)
*
|
1993-03-03 |
1994-09-15 |
E.I. Du Pont De Nemours And Company |
Production of glycolate oxidase in methylotrophic yeast
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
CA2202351A1
(en)
*
|
1994-10-18 |
1996-04-25 |
George Phillip Vlasuk |
Nematode-extracted serine protease inhibitors and anticoagulant proteins
|
US5945275A
(en)
*
|
1994-10-18 |
1999-08-31 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5866543A
(en)
*
|
1995-06-05 |
1999-02-02 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5872098A
(en)
*
|
1995-06-05 |
1999-02-16 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5866542A
(en)
*
|
1994-10-18 |
1999-02-02 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5863894A
(en)
*
|
1995-06-05 |
1999-01-26 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
HU225126B1
(en)
*
|
1994-10-18 |
2006-06-28 |
Dendreon Corp |
Nematode-extracted serine protease inhibitors and anticoagulant proteins
|
PT848755E
(pt)
|
1995-09-08 |
2003-12-31 |
Genentech Inc |
Proteina relacionada com o vegf
|
EP0862640A2
(en)
*
|
1995-11-09 |
1998-09-09 |
ZymoGenetics, Inc. |
Production of gad65 in methylotrophic yeast
|
US5716808A
(en)
*
|
1995-11-09 |
1998-02-10 |
Zymogenetics, Inc. |
Genetic engineering of pichia methanolica
|
US5955349A
(en)
*
|
1996-08-26 |
1999-09-21 |
Zymogenetics, Inc. |
Compositions and methods for producing heterologous polypeptides in Pichia methanolica
|
ATE449849T1
(de)
|
1996-01-08 |
2009-12-15 |
Genentech Inc |
Ob rezeptor-variante und liganden
|
US5854039A
(en)
*
|
1996-07-17 |
1998-12-29 |
Zymogenetics, Inc. |
Transformation of pichia methanolica
|
US5736383A
(en)
*
|
1996-08-26 |
1998-04-07 |
Zymogenetics, Inc. |
Preparation of Pichia methanolica auxotrophic mutants
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
MX9605082A
(es)
|
1996-10-24 |
1998-04-30 |
Univ Autonoma De Nuevo Leon |
Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
|
US6100076A
(en)
|
1997-01-31 |
2000-08-08 |
Genentech, Inc. |
O-fucosyltransferase
|
DE69737457T2
(de)
|
1997-01-31 |
2007-11-29 |
Genentech, Inc., South San Francisco |
O-fukosyltransferase
|
WO1999021999A2
(en)
|
1997-10-29 |
1999-05-06 |
Genentech, Inc. |
Wnt-1 inducible genes
|
DE69842174D1
(de)
|
1997-04-07 |
2011-04-21 |
Genentech Inc |
Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
|
ES2273415T3
(es)
|
1997-04-07 |
2007-05-01 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US6265186B1
(en)
|
1997-04-11 |
2001-07-24 |
Dsm N.V. |
Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
IL135704A
(en)
|
1997-10-29 |
2008-04-13 |
Genentech Inc |
Method for the diagnosis of cancerous growth of cells by identifying the secreted polypeptide WISP-1 affected by WNT-1
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
DK1076703T4
(da)
|
1998-05-15 |
2011-03-28 |
Genentech Inc |
Terapeutiske anvendelser af IL-17-homologe polypeptider
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6316245B1
(en)
*
|
1998-09-16 |
2001-11-13 |
Biongene Co., Ltd. |
Mutant cells of Pichia
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
EP1484338B1
(en)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
US6720174B1
(en)
|
1999-01-28 |
2004-04-13 |
Novozymes A/S |
Phytases
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
SI1189641T1
(sl)
|
1999-06-25 |
2009-12-31 |
Genentech Inc |
Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2
|
WO2001029078A2
(en)
*
|
1999-10-15 |
2001-04-26 |
Heska Corporation |
Method for production and use of mite group 1 proteins
|
EP1690872A3
(en)
|
1999-12-01 |
2006-08-23 |
Genentech, Inc. |
Composition and methods for the diagnosis of tumours
|
EP1897947B1
(en)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
WO2001077351A1
(en)
*
|
2000-04-07 |
2001-10-18 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Vectors and methods for dual protein expression in pichia pastoris and escherichia coli
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2075253A1
(en)
|
2000-06-23 |
2009-07-01 |
Genentech, Inc. |
Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
|
US7598055B2
(en)
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
US7625756B2
(en)
*
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US8697394B2
(en)
*
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
US7449308B2
(en)
*
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US7029872B2
(en)
|
2000-06-28 |
2006-04-18 |
Glycofi, Inc |
Methods for producing modified glycoproteins
|
EP1294910B1
(en)
|
2000-06-30 |
2008-11-19 |
VIB vzw |
Protein glycosylation modification in pichia pastoris
|
US7009045B2
(en)
*
|
2000-07-14 |
2006-03-07 |
Archer-Daniels-Midland Company |
Transformation systems for flavinogenic yeast
|
DK1303293T3
(da)
|
2000-07-27 |
2009-03-30 |
Genentech Inc |
Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
|
EP2014298A3
(en)
|
2000-08-24 |
2009-10-07 |
Genentech, Inc. |
Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US7265208B2
(en)
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
AU2002254753C1
(en)
|
2001-05-01 |
2008-09-18 |
The Regents Of The University Of California |
Fusion molecules and methods for treatment of immune diseases
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
ES2372321T3
(es)
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
US7060278B2
(en)
|
2001-08-29 |
2006-06-13 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
NZ531674A
(en)
|
2001-09-18 |
2009-03-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
KR20070087247A
(ko)
|
2002-01-02 |
2007-08-27 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
WO2003072035A2
(en)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2486252C
(en)
|
2002-06-07 |
2012-07-24 |
Genentech, Inc. |
Methods for screening for agents that modulate hepatocellular carcinoma development
|
IL165717A0
(en)
|
2002-06-26 |
2006-01-15 |
Flanders Interuniversity Inst |
A strain of methylotrophic yeast for producing proteins
|
PT2263691E
(pt)
|
2002-07-15 |
2012-11-12 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
|
SI1543038T2
(sl)
|
2002-09-11 |
2020-12-31 |
Genentech, Inc. |
Čiščenje proteinov
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP1539228B1
(en)
|
2002-09-11 |
2010-12-29 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
JP2006515165A
(ja)
|
2002-09-16 |
2006-05-25 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための新規組成物と方法
|
EP2500438A3
(en)
|
2002-09-25 |
2012-11-28 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
EP2322203A3
(en)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP1581169A4
(en)
|
2002-11-08 |
2008-09-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
|
EP1572116A4
(en)
|
2002-11-26 |
2007-12-12 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
DE60335602D1
(de)
*
|
2002-12-18 |
2011-02-17 |
Roche Diagnostics Gmbh |
Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
|
ATE387494T1
(de)
*
|
2002-12-20 |
2008-03-15 |
Hoffmann La Roche |
Hitzelabile desoxyribonuklease i-varianten
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
EP2526960A1
(en)
|
2003-03-12 |
2012-11-28 |
Genentech, Inc. |
Use of BV8 and/or EG-VEGF to promote hematopoiesis
|
EP1460425A1
(en)
*
|
2003-03-17 |
2004-09-22 |
Boehringer Mannheim Gmbh |
Deglycosylated enzymes for conjugates
|
EP1610820B2
(en)
|
2003-04-04 |
2013-08-21 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
CA2526085A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
CN1802386B
(zh)
|
2003-06-12 |
2010-12-15 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
ES2366830T3
(es)
*
|
2003-08-25 |
2011-10-25 |
Funzyme Biotechnologies Sa |
Nuevas proteínas fúngicas y ácidos nucelicos que codifican las mismas.
|
JP4901478B2
(ja)
|
2003-11-17 |
2012-03-21 |
ジェネンテック, インコーポレイテッド |
造血系起源の腫瘍の治療のための組成物と方法
|
DE602004025192D1
(de)
*
|
2003-12-05 |
2010-03-11 |
Roche Diagnostics Gmbh |
Rekombinante Carboxypeptidase B und ihre Aufreinigung
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
JP2007521823A
(ja)
|
2004-02-13 |
2007-08-09 |
ノボザイムス アクティーゼルスカブ |
プロテアーゼ変異型
|
KR100942849B1
(ko)
|
2004-03-30 |
2010-02-17 |
글락소 그룹 리미티드 |
면역글로불린
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
PL1771474T3
(pl)
|
2004-07-20 |
2010-07-30 |
Genentech Inc |
Inhibitory białka angiopoetyno-4-podobnego, kombinacje i ich zastosowanie
|
US20090136490A1
(en)
|
2004-11-10 |
2009-05-28 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods for use
|
JP2008526883A
(ja)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
ES2368500T3
(es)
|
2005-08-16 |
2011-11-17 |
Novo Nordisk A/S |
Método para producir polipéptidos de insulina maduros.
|
PT1926749E
(pt)
*
|
2005-09-14 |
2011-09-29 |
Sanofi Aventis Deutschland |
Clivagem de precursores de insulinas por uma variante de tripsina
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
CN101360826B
(zh)
|
2005-11-18 |
2014-04-30 |
格兰马克药品股份有限公司 |
抗α2整联蛋白抗体及它们的用途
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
EP2050335A1
(en)
|
2006-02-17 |
2009-04-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
EP2389951A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
CA2911000A1
(en)
|
2006-04-05 |
2007-10-18 |
Min W. Wan |
Antibody purification
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
EP2082645A1
(en)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
AU2007244683A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
EP2024393A2
(en)
|
2006-05-15 |
2009-02-18 |
Sea Lane Biotechnologies,llc. |
Neutralizing antibodies to influenza viruses
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
ES2523640T3
(es)
|
2006-06-21 |
2014-11-28 |
Musc Foundation For Research Development |
Direccionamiento del factor H del complemento para el tratamiento de enfermedades
|
NO346945B1
(no)
|
2006-06-30 |
2023-03-13 |
Novo Nordisk As |
Anti-NKG2A-antistoffer og anvendelser derav
|
EP2059535B1
(en)
|
2006-08-18 |
2013-11-06 |
Novartis AG |
Prlr-specific antibody and uses thereof
|
JP5503968B2
(ja)
|
2006-09-27 |
2014-05-28 |
ノボ・ノルデイスク・エー/エス |
成熟インスリンポリペプチドの作製方法
|
SI2087002T1
(sl)
|
2006-10-27 |
2014-11-28 |
Lpath, Inc. |
Sestavki in postopki za vezavo sfingozin-1-fosfata
|
US8444970B2
(en)
|
2006-10-27 |
2013-05-21 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
AU2007353396C1
(en)
|
2006-11-02 |
2013-06-27 |
Biomolecular Holdings Llc |
Hybrid immunoglobulins with moving parts
|
KR20090082480A
(ko)
|
2006-11-14 |
2009-07-30 |
제넨테크, 인크. |
뉴런 재생의 조절인자
|
CA2670471A1
(en)
|
2006-11-22 |
2008-06-05 |
Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US8288110B2
(en)
*
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
NZ577933A
(en)
|
2007-01-22 |
2011-12-22 |
Genentech Inc |
Polyelectrolyte precipitation and purification of antibodies
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
CA2676790A1
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
EP2508612B1
(en)
*
|
2007-04-03 |
2017-11-29 |
Oxyrane UK Limited |
Glycosylation of molecules
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
AU2008260135A1
(en)
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
RU2473563C2
(ru)
|
2007-06-07 |
2013-01-27 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
CN101361968B
(zh)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗脂肪肝中的应用
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
RU2498991C2
(ru)
|
2007-10-30 |
2013-11-20 |
Дженентек, Инк. |
Очистка антител с помощью катионообменной хроматографии
|
EP2209807A1
(en)
|
2007-11-08 |
2010-07-28 |
Genentech, Inc. |
Anti-factor b antibodies and their uses
|
PT2220116E
(pt)
|
2007-11-12 |
2012-12-07 |
Theraclone Sciences Inc |
Composições e métodos para a terapia e o diagnóstico da gripe
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
DK2657253T3
(da)
|
2008-01-31 |
2017-10-09 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
AU2009223846B2
(en)
|
2008-03-03 |
2014-11-20 |
Abbvie Inc. |
Methods for transforming yeast
|
EP2257571B1
(en)
|
2008-03-10 |
2015-03-04 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
WO2009121004A2
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to viral antigens
|
SG10201402815VA
(en)
|
2008-04-09 |
2014-09-26 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
BRPI0912003A2
(pt)
|
2008-05-06 |
2016-07-12 |
Genentech Inc |
afinidade de variantes de crig maturadas
|
JP2011523560A
(ja)
|
2008-06-02 |
2011-08-18 |
ダナ−ファーバー キャンサー インスティテュート インク. |
Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド
|
EP3604324B1
(en)
|
2008-08-14 |
2024-02-28 |
Genentech, Inc. |
Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
|
US8937046B2
(en)
|
2008-09-22 |
2015-01-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Modulating the alternative complement pathway
|
EP2921501A1
(en)
|
2008-10-20 |
2015-09-23 |
Abbvie Inc. |
Isolation and purification of antibodies using Protein A affinity chromatography
|
KR20110081862A
(ko)
|
2008-10-22 |
2011-07-14 |
제넨테크, 인크. |
축삭 변성의 조절
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
MX2011004696A
(es)
|
2008-11-06 |
2011-10-14 |
Glenmark Pharmaceuticals Sa |
Tratamiento con anticuerpos anti-integrina alfa2.
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
WO2010078376A2
(en)
|
2008-12-30 |
2010-07-08 |
Ventana Medical Systems, Inc. |
Fc-specific polymer-conjugated antibodies and their diagnostic use
|
MX362028B
(es)
|
2009-02-03 |
2019-01-04 |
Amunix Pharmaceuticals Inc |
Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
US8466260B2
(en)
|
2009-04-01 |
2013-06-18 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
US8609101B2
(en)
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
EP2432803A2
(en)
|
2009-05-20 |
2012-03-28 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
MX354555B
(es)
|
2009-06-08 |
2018-03-09 |
Amunix Operating Inc |
Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
|
ES2705249T3
(es)
|
2009-06-08 |
2019-03-22 |
Amunix Operating Inc |
Polipéptidos reguladores de glucosa y métodos para su producción y uso
|
JP2012533306A
(ja)
|
2009-07-15 |
2012-12-27 |
アボット・ラボラトリーズ |
機械的伝達による細胞産生の強化
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
KR101764449B1
(ko)
|
2009-09-01 |
2017-08-02 |
제넨테크, 인크. |
변형된 단백질 a 용리를 통한 증진된 단백질 정제
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
JP5990102B2
(ja)
|
2009-09-29 |
2016-09-07 |
ユニフェルシテイト ヘント |
ホスホ−6−マンノースへのマンノース−1−ホスホ−6−マンノース結合の加水分解
|
CA2777717C
(en)
|
2009-10-15 |
2021-05-25 |
Genentech, Inc. |
Chimeric fibroblast growth factors with altered receptor specificity
|
LT3037104T
(lt)
|
2009-10-20 |
2020-09-10 |
Abbvie Inc. |
Anti-il-13 antikūnų izoliavimas ir gryninimas, naudojant afininę baltymo a chromatografiją
|
CN102573855A
(zh)
|
2009-10-22 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック, インコーポレイテッド |
樹状突起棘の密度を促す方法
|
BR112012011980A2
(pt)
|
2009-11-19 |
2021-09-08 |
Oxyrane Uk Limited |
Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas
|
SG10201408598XA
(en)
|
2009-11-30 |
2015-02-27 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
WO2011073235A1
(en)
|
2009-12-18 |
2011-06-23 |
Csl Ltd. |
Method of purifying polypeptides
|
EP2515932A2
(en)
|
2009-12-21 |
2012-10-31 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Synergic action of a prolyl protease and tripeptidyl proteases
|
RU2609658C2
(ru)
|
2009-12-21 |
2017-02-02 |
Дженентек, Инк. |
Состав, содержащий антитело
|
US8940303B2
(en)
|
2010-01-28 |
2015-01-27 |
Glaxo Group Limited |
CD127 binding proteins
|
MA34057B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Compositions et methodes pour le diagnostic et le traitement d'une tumeur
|
MX2012009809A
(es)
|
2010-02-23 |
2012-11-23 |
Sanofi Sa |
Anticuerpos anti - integrina alfa2 y sus usos.
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
EP3178851B1
(en)
|
2010-03-31 |
2020-04-29 |
Boehringer Ingelheim International GmbH |
Anti-cd40 antibodies
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
PE20130460A1
(es)
|
2010-05-03 |
2013-04-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
RU2614125C2
(ru)
|
2010-05-28 |
2017-03-22 |
Дженентек, Инк. |
Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
|
JP2013534515A
(ja)
|
2010-06-01 |
2013-09-05 |
モナシュ ユニバーシティ |
プロセシングされていない受容体型チロシンキナーゼc−METに対する抗体
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
ES2690760T3
(es)
|
2010-06-25 |
2018-11-22 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Polipéptido de flagelina como agonista de TLR5 para su uso en el tratamiento de infecciones de las vías respiratorias
|
WO2012010635A1
(en)
|
2010-07-22 |
2012-01-26 |
Glaxosmithkline Biologicals S.A. |
Novel antigen binding proteins
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ, インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
CN102380091A
(zh)
|
2010-08-31 |
2012-03-21 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗病毒性肝炎中的应用
|
EP2926830B1
(en)
|
2010-08-31 |
2017-08-02 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
WO2012036884A2
(en)
|
2010-09-15 |
2012-03-22 |
Aligna Technologies, Inc. |
Bioproduction of aromatic chemicals from lignin-derived compounds
|
KR20130114143A
(ko)
|
2010-09-20 |
2013-10-16 |
애브비 인코포레이티드 |
모사 이동층 크로마토그래피를 이용한 항체의 정제
|
CA2812870C
(en)
|
2010-09-29 |
2020-06-09 |
Oxyrane Uk Limited |
Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
|
JP6131190B2
(ja)
|
2010-09-29 |
2017-05-17 |
オキシレイン ユーケー リミテッド |
リン酸化n−グリカンの脱マンノシル化
|
DK2625197T3
(da)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened-mutant og fremgangsmåder til anvendelse af samme
|
KR101571940B1
(ko)
|
2010-10-08 |
2015-11-25 |
상하이 켁신 바이오테크 씨오., 엘티디. |
면역성 혈소판 감소증과 관련된 모에신 단편
|
JP5868410B2
(ja)
|
2010-10-08 |
2016-02-24 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
再生不良性貧血と関連しているモエシン断片
|
KR101641756B1
(ko)
|
2010-10-08 |
2016-07-21 |
상하이 켁신 바이오테크 씨오., 엘티디. |
모에신 단편 및 그의 용도
|
WO2012045281A1
(en)
|
2010-10-08 |
2012-04-12 |
Shanghai Kexin Biotech Co., Ltd. |
Diagnostic and therapeutic uses of moesin fragments
|
US9345764B2
(en)
|
2010-10-08 |
2016-05-24 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin modulators and uses thereof
|
EP2635601B1
(en)
|
2010-11-04 |
2016-07-20 |
Boehringer Ingelheim International GmbH |
Anti-il-23 antibodies
|
JP6296536B2
(ja)
|
2010-11-05 |
2018-03-20 |
メドベット サイエンス ピーティーワイエルティーディーMedvet Science Pty Ltd |
内皮前駆細胞のマーカーおよびその使用
|
RU2013125777A
(ru)
|
2010-11-05 |
2014-12-10 |
Эббви Инк. |
Эффективный и экономичный скрининг добавок для создания сред определенного химического состава при культивировании клеток
|
WO2012064619A1
(en)
*
|
2010-11-10 |
2012-05-18 |
Merck Sharp & Dohme Corp. |
Pichia pastoris loci encoding enzymes in the proline biosynthetic pathway
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
PT2654790T
(pt)
|
2010-12-22 |
2019-05-16 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticorpo modificado com semivida melhorada
|
BR112013020743A2
(pt)
|
2011-02-14 |
2016-10-18 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
WO2012122528A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
US20120315277A1
(en)
|
2011-03-15 |
2012-12-13 |
Theraclone Sciences, Inc. |
Compositions and Methods for the Therapy and Diagnosis of Influenza
|
EP2689250A1
(en)
|
2011-03-23 |
2014-01-29 |
AbbVie Inc. |
Methods and systems for the analysis of protein samples
|
MY189494A
(en)
|
2011-03-31 |
2022-02-16 |
Genentech Inc |
Methods of administering beta7 integrin antagonists
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
CN108424451B
(zh)
|
2011-06-03 |
2022-09-09 |
佐马技术有限公司 |
对TGF-β具有特异性的抗体
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
EA036047B1
(ru)
|
2011-07-11 |
2020-09-18 |
Икнос Сайенсиз Са |
Антитела, которые связываются с ox40, и их применение
|
RU2014109985A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Ингибирование ангиогенеза в рефрактерных опухолях
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
EP2758438A1
(en)
|
2011-09-23 |
2014-07-30 |
Amgen Research (Munich) GmbH |
Bispecific binding molecules for 5t4 and cd3
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
PL2780373T3
(pl)
|
2011-11-16 |
2020-03-31 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty il-36r
|
US9988611B2
(en)
|
2011-12-01 |
2018-06-05 |
Ap Biosciences, Inc. |
Protein inhibitors to complement and VEGF pathways and methods of use thereof
|
CN104471068A
(zh)
|
2011-12-16 |
2015-03-25 |
布拉斯科南美公司(巴西) |
经修饰的微生物和使用其制造丁二烯的方法
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
TR201815709T4
(tr)
|
2011-12-22 |
2018-11-21 |
Hoffmann La Roche |
İyon değişim membranı kromatografisi.
|
BR112014015933A2
(pt)
|
2011-12-30 |
2019-09-24 |
Oxyrane Uk Ltd |
métodos e materiais para reduzir a degradação das proteínas recombinantes
|
WO2013109342A1
(en)
|
2012-01-19 |
2013-07-25 |
University Of Cincinnati |
Method of treating diabetes using non-glycosylated apolipoprotein a-iv
|
AU2013215332A1
(en)
|
2012-01-31 |
2014-09-04 |
Genentech, Inc. |
Anti-Ig-E M1' antibodies and methods using same
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
AU2013234042B2
(en)
|
2012-03-15 |
2017-11-02 |
Oxyrane Uk Limited |
Methods and materials for treatment of Pompe's disease
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
PT2841087T
(pt)
|
2012-04-27 |
2017-11-27 |
Us Health |
Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos
|
PL3326649T3
(pl)
|
2012-05-03 |
2022-04-25 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-il-23p19
|
WO2013177118A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
US10232019B2
(en)
|
2012-07-25 |
2019-03-19 |
University Of Cincinnati |
Method of treating hyperglycemic disorders using apolipoprotein AIV
|
JP2015524808A
(ja)
|
2012-07-25 |
2015-08-27 |
ユニバーシティ・オブ・シンシナティ |
アポリポタンパク質aivを用いたi型糖尿病の治療法
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN105377288B
(zh)
|
2012-11-05 |
2019-11-15 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽的组合物制备药物的用途
|
AP2015008605A0
(en)
|
2013-01-02 |
2015-07-31 |
Glenmark Pharmaceuticals Sa |
Antibodies that bind to tl1a and their uses
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
WO2014136065A2
(en)
|
2013-03-05 |
2014-09-12 |
Oxyrane Uk Limited |
Production of catalytically active type i sulfatase
|
BR112015022210A8
(pt)
|
2013-03-13 |
2018-01-23 |
Genentech Inc |
formulações de anticorpo
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
MX369671B
(es)
|
2013-03-13 |
2019-11-15 |
Genentech Inc |
Formulaciones con oxidacion reducida.
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
CA2904169C
(en)
|
2013-03-13 |
2021-12-07 |
Genentech, Inc. |
Formulations with reduced oxidation
|
BR112015017307A2
(pt)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
composições de espécies com baixa acidez e métodos para produção e uso das mesmas
|
WO2014151901A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Improvement of mammalian cell culture performance through surfactant supplementation of feed media
|
WO2014159554A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
EP2968544A4
(en)
|
2013-03-15 |
2016-10-12 |
Hoffmann La Roche |
CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
|
EP2968495B1
(en)
|
2013-03-15 |
2019-07-03 |
Daniel J. Capon |
Hybrid immunoglobulin containing non-peptidyl linkage
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
ES2798307T3
(es)
|
2013-03-15 |
2020-12-10 |
Hoffmann La Roche |
Composiciones de cultivo de células con antioxidantes y procedimientos para la producción de polipéptidos
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
ES2753950T3
(es)
|
2013-03-15 |
2020-04-15 |
Amgen Res Munich Gmbh |
Moléculas de unión monocatenarias que comprenden ABP del extremo N
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
JP6574754B2
(ja)
|
2013-03-19 |
2019-09-11 |
ベイジン シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体関連疾患を処置するための抗体及び方法
|
WO2014160753A1
(en)
|
2013-03-27 |
2014-10-02 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
LT3004162T
(lt)
|
2013-05-31 |
2020-06-10 |
Genentech, Inc. |
Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
|
JP2016521701A
(ja)
|
2013-06-07 |
2016-07-25 |
ノヴォ ノルディスク アー/エス |
成熟インスリンポリペプチドを作製するための方法
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
WO2015048520A1
(en)
|
2013-09-27 |
2015-04-02 |
Genentech, Inc. |
Anti-pdl1 antibody formulations
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
CN112353943A
(zh)
|
2013-12-17 |
2021-02-12 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
WO2015102341A1
(ko)
|
2013-12-30 |
2015-07-09 |
재단법인 의약바이오컨버젼스연구단 |
항 krs 모노클로날 항체 및 이의 용도
|
BR112016014731A2
(pt)
|
2014-01-31 |
2017-09-19 |
Boehringer Ingelheim Int |
Anticorpos anti-baff
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3116486B1
(en)
|
2014-03-14 |
2019-12-04 |
Daniel J. Capon |
Hybrid immunoglobulin containing non-peptidyl linkage
|
CA2943357C
(en)
|
2014-03-25 |
2023-06-27 |
Genentech, Inc. |
Methods of preparing a poloxamer for use in cell culture medium
|
RU2016136716A
(ru)
|
2014-03-27 |
2018-04-28 |
Дженентек, Инк. |
Способы диагностики и лечения воспалительного заболевания кишечника
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
US8961992B1
(en)
|
2014-04-02 |
2015-02-24 |
Tunitas Therapeutics, Inc. |
Epsigam fusion protein
|
EP3149187B1
(en)
|
2014-05-30 |
2020-04-29 |
Braskem S.A. |
Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
|
US20170183376A1
(en)
|
2014-06-24 |
2017-06-29 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
US20170226552A1
(en)
|
2014-07-03 |
2017-08-10 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
JP2017524359A
(ja)
|
2014-07-24 |
2017-08-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Il−23a関連疾患の処置に有用なバイオマーカー
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
WO2016016859A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
BR112017011325A2
(pt)
|
2014-12-03 |
2020-07-21 |
Genentech, Inc. |
?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
|
WO2016120764A1
(en)
|
2015-01-26 |
2016-08-04 |
Centre Hospitalier Universitaire Vaudois (Chuv) |
Aspergillus oryzae prolyl endopeptidases and use thereof in degradation of polypeptides
|
EP3253794A1
(en)
|
2015-02-04 |
2017-12-13 |
Boehringer Ingelheim International GmbH |
Methods of treating inflammatory diseases
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP2018507868A
(ja)
|
2015-02-26 |
2018-03-22 |
ジェネンテック, インコーポレイテッド |
インテグリンベータ7アンタゴニスト及びクローン病の治療方法
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
WO2016144773A1
(en)
|
2015-03-06 |
2016-09-15 |
Abbvie Inc. |
Arabinosylated glycoproteins
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
EA201792282A1
(ru)
|
2015-04-14 |
2018-04-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы лечения заболеваний
|
HUE061730T2
(hu)
|
2015-04-17 |
2023-08-28 |
Amgen Res Munich Gmbh |
Bispecifikus antitest-konstrukciók CDH3-hoz és CD3-hoz
|
JP6884111B2
(ja)
|
2015-05-29 |
2021-06-09 |
ジェネンテック, インコーポレイテッド |
癌におけるpd−l1プロモーターのメチル化
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
IL293385A
(en)
|
2015-08-11 |
2022-07-01 |
Omniab Inc |
New anti–pd–1 antibodies
|
JP7175760B2
(ja)
|
2015-09-07 |
2022-11-21 |
ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) |
新規なigfr様レセプター及びその使用
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
US11040114B2
(en)
|
2015-12-24 |
2021-06-22 |
Oxyrane Uk Limited |
Human alpha-N-acetylgalactosaminidase polypeptide
|
SG11201804961UA
(en)
|
2015-12-30 |
2018-07-30 |
Genentech Inc |
Formulations with reduced degradation of polysorbate
|
BR112018013071A2
(pt)
|
2015-12-30 |
2018-12-11 |
Genentech Inc |
uso de derivados de triptofano para formulações de proteínas
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
SI3411404T1
(sl)
|
2016-02-03 |
2023-01-31 |
Amgen Research (Munich) Gmbh |
Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico
|
CR20180420A
(es)
|
2016-02-03 |
2018-12-05 |
Amgen Inc |
Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
JP6430025B2
(ja)
|
2016-03-15 |
2018-11-28 |
中外製薬株式会社 |
Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
RU2744959C2
(ru)
|
2016-03-23 |
2021-03-17 |
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд |
Новые анти-pd-l1 антитела
|
US11510966B2
(en)
|
2016-04-15 |
2022-11-29 |
Evive Biotechnology (Shanghai) Ltd |
Use of IL-22 in treating necrotizing enterocolitis
|
AU2017250583A1
(en)
|
2016-04-15 |
2018-08-16 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
US10851159B2
(en)
|
2016-06-02 |
2020-12-01 |
Bloom Diagnostics Ag |
Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
|
CN109803680B
(zh)
|
2016-08-01 |
2024-05-17 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
KR20190049866A
(ko)
|
2016-09-20 |
2019-05-09 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 항-pcsk9 항체
|
JP2019534710A
(ja)
|
2016-09-28 |
2019-12-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
インターロイキン2に結合する抗体およびその使用
|
WO2018071504A2
(en)
|
2016-10-14 |
2018-04-19 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
US11007254B2
(en)
|
2016-10-17 |
2021-05-18 |
Musc Foundation For Research Development |
Compositions and methods for treating central nervous system injury
|
US20190352374A1
(en)
|
2017-01-30 |
2019-11-21 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel igfr_like 2 receptor and uses thereof
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP4095161A1
(en)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Novel anti-trkb antibodies
|
WO2018182284A1
(ko)
|
2017-03-27 |
2018-10-04 |
재단법인 의약바이오컨버젼스연구단 |
세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
|
CN110461877A
(zh)
|
2017-03-27 |
2019-11-15 |
勃林格殷格翰国际有限公司 |
抗il-36r抗体联合治疗
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
AR111773A1
(es)
|
2017-05-05 |
2019-08-21 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
US11827669B2
(en)
|
2017-07-19 |
2023-11-28 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
AU2018326805B2
(en)
|
2017-09-01 |
2023-11-30 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
|
US11339221B2
(en)
|
2017-11-01 |
2022-05-24 |
Tufts Medical Center, Inc. |
Bispecific antibody constructs and methods of use
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
WO2019164891A1
(en)
|
2018-02-21 |
2019-08-29 |
Celgene Corporation |
Bcma-binding antibodies and uses thereof
|
KR102340989B1
(ko)
|
2018-03-28 |
2021-12-20 |
에이비온 주식회사 |
클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
BR112020024078A2
(pt)
|
2018-06-29 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpos anti-cd40 para uso no tratamento de doença autoimune
|
WO2020033485A1
(en)
|
2018-08-08 |
2020-02-13 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
KR20210068408A
(ko)
|
2018-09-28 |
2021-06-09 |
암젠 인크 |
가용성 bcma에 대한 항체
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
AU2019365391A1
(en)
|
2018-10-23 |
2021-04-29 |
Consejo Superior De Investigaciones Científicas |
Antibodies specific for glycosylated ApoJ and uses thereof
|
WO2020136232A1
(en)
|
2018-12-28 |
2020-07-02 |
Transgene Sa |
Immunosuppressive m2 protein
|
WO2020181142A1
(en)
|
2019-03-06 |
2020-09-10 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
CN114096559A
(zh)
|
2019-03-27 |
2022-02-25 |
蒂嘉特克斯公司 |
工程化iga抗体及其使用方法
|
AR122266A1
(es)
|
2019-05-09 |
2022-08-31 |
Boehringer Ingelheim Int |
Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
|
CN114206935B
(zh)
|
2019-05-24 |
2024-01-12 |
三优生物医药(上海)有限公司 |
新型cldn18.2结合分子
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
JP2022545917A
(ja)
|
2019-08-27 |
2022-11-01 |
トニックス ファーマ リミテッド |
修飾tff2ポリペプチド
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
KR102442204B1
(ko)
|
2019-09-20 |
2022-09-08 |
경북대학교 산학협력단 |
Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
JP2023522037A
(ja)
|
2020-04-15 |
2023-05-26 |
ジェネンテック, インコーポレイテッド |
銅損の軽減
|
US20210380696A1
(en)
|
2020-05-26 |
2021-12-09 |
Boehringer Ingelheim International Gmbh |
Anti-pd-1 antibodies
|
PE20231078A1
(es)
|
2020-06-02 |
2023-07-17 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
EP4165076A1
(en)
|
2020-06-15 |
2023-04-19 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus antibodies and fragments thereof
|
IL299039A
(en)
|
2020-06-16 |
2023-02-01 |
Genentech Inc |
Methods and preparations for the treatment of triple-negative breast cancer
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
CA3199976A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Research (Munich) Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
TW202225188A
(zh)
|
2020-11-06 |
2022-07-01 |
德商安美基研究(慕尼黑)公司 |
與cd3結合的多肽構建體
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
EP4263597A2
(en)
|
2020-12-18 |
2023-10-25 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
WO2022212831A1
(en)
|
2021-04-02 |
2022-10-06 |
Amgen Inc. |
Mageb2 binding constructs
|
CN117321086A
(zh)
|
2021-04-26 |
2023-12-29 |
轩竹生物科技股份有限公司 |
一种双特异抗体偶联物
|
CA3226102A1
(en)
|
2021-07-23 |
2023-01-26 |
Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Igfr-l1 antibodies and uses thereof
|
WO2023105087A1
(en)
|
2021-12-10 |
2023-06-15 |
Tubulis Gmbh |
Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
|
EP4238988A1
(en)
|
2022-03-01 |
2023-09-06 |
Consejo Superior De Investigaciones Científicas |
Antibodies against sars-cov-2 and uses thereof
|
WO2023173011A1
(en)
|
2022-03-09 |
2023-09-14 |
Bristol-Myers Squibb Company |
Transient expression of therapeutic proteins
|
WO2024032891A1
(en)
|
2022-08-11 |
2024-02-15 |
Vib Vzw |
Glyco-engineered yeast for therapeutic protein production
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
US20240182596A1
(en)
|
2022-10-18 |
2024-06-06 |
Tubulis Gmbh |
Anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
|
WO2024083953A1
(en)
|
2022-10-18 |
2024-04-25 |
Tubulis Gmbh |
Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
|